People with Crohn’s disease (CD) often experience intestinal fibrosis, a result of chronic inflammation that thickens the gut wall, forms scar tissues and narrows the digestive tract, leading to blockages. This persistent fibrotic process necessitates multiple surgeries over a person’s lifetime. Currently, there are no targeted medications for fibrosis due to a lack of understanding […]
In 1848, a German philosopher, Ludwig Feuerbach, first used the phrase, “We are what we eat.” This famous statement is particularly true in Inflammatory Bowel Disease (IBD) where a western diet lacking in plant derived components is a well-recognised risk factor. However, we still do not understand how the food we eat can contribute to […]
The bacteria in the human colon can influence gastrointestinal lining cells—intestinal epithelial cells (IECs)—and immune cells within the intestines and throughout the body. One way that bacteria do this is through their metabolites, the chemicals they produce. By influencing IECs and immune cells, gut bacterial metabolites affect resistance and susceptibility to Inflammatory Bowel Disease (IBD), […]
Intestinal fungi, collectively known as the mycobiota, have emerged as significant contributors to intestinal disease severity. Our prior research demonstrated the efficacy of fecal microbiota transplantation in inducing clinical responses in UC patients associated with decreased fungal colonization over time. Further investigations in mouse models and UC patients revealed that fungi exacerbate disease severity through […]
Patients with Inflammatory Bowel Disease (IBD) have dysfunctions in gut motility (the movement of muscles in the gastrointestinal tract). Currently, most available therapeutics developed to directly target the gut fail to stabilize symptoms, suggesting that dysfunctions in gut motility could arise from pathological changes occurring outside the gut. Intriguingly, gut motility problems also occur at […]
Three year grant to support ABGH in expanding its Rising Mentorship Program, building organizational capacity and launching a research grant program focused on Inflammatory Bowel Disease. Funding will support mentorship for Black medical trainees, the hiring of a full-time Executive Director and six research projects led by early-career investigators.
Azora Therapeutics is developing a novel small molecule (AT177) for the treatment of refractory ulcerative colitis (UC). UC is a chronic inflammatory disease of the colon that affects over one million individuals in the US and is associated with poor quality of life. Efficacy of currently available therapy is suboptimal and most patients cannot sustain […]
To support engagement of a bargaining facilitator and development of a case study on their unionization process.
To support Oakland’s primary nonprofit organization focused on expanding affordable housing for early elementary teachers who are responsible for teaching early literacy.
Supporting the successful transition of the Cal Shakes scene shop (“The Shop”) from a department of California Shakespeare Theater (“Cal Shakes”) into its own standalone nonprofit.
